Asymmetric Dimethyl Arginine and nitric oxide in chronic renal disease patients with cardiac and non cardiac complications
Sahar Eladawy1; Seham Sabry1 and Rayyh A.M.Saleh2
1Internal Medicine and 2Clinical pathology Departments, Faculty of Medicine, Al Azhar University
Abstract: Asymmetrical dimethylarginine (ADMA) is inhibitor of nitric-oxide synthase, which has been linked to endothelial dysfunction and atherosclerosis in the general population, is raised in patients with end-stage renal disease and could contribute to the high cardiovascular risk in patients with chronic renal failure. Aim of the work, the aim of this study is to evaluate the levels of ADMA and NO and their association with cardiovascular disease in chronic renal disease patients. Patient and methods. Thirty patients with chronic renal failure under hemodialysis three setions//week and fifteen apparently healthy individuals as a control group .they were selected from internal medicine department (nephrology unit), Al Zahra university hospital underwent. Complete history taking, full clinical examination, laboratory investigations as complete blood picture, blood urea, serum creatinine, serum Na, serum K, cholesterol, triglyceride, echocardiography, ADMA, NO. Conclusion, Elevated plasma ADMA level in the chronic renal failure patients. Also plasma ADMA levels predict cardiovascular events in patients with chronic renal failure.
[Sahar Eladawy, Seham Sabry and Rayyh A.M.Saleh. Asymmetric Dimethyl Arginine and nitric oxide in chronic renal disease patients with cardiac and non cardiac complications. J Am Sci 2012;8(10):861-865]. (ISSN: 1545-1003). http://www.jofamericanscience.org. 115